Influenza Vaccine Effectiveness Against Hospitalization in Fully and Partially Vaccinated Children in Israel: 2015–2016, 2016–2017, and 2017–2018

• Published in: Clinical infectious diseases Vol. 69; no. 12; pp. 2153 - 2161
• Main Authors: Segaloff, Hannah E, Leventer-Roberts, Maya, Riesel, Dan, Malosh, Ryan E, Feldman, Becca S, Shemer-Avni, Yonat, Key, Calanit, Monto, Arnold S, Martin, Emily T, Katz, Mark A
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 27.11.2019
• Subjects: influenza; vaccine effectiveness; Israel; hospitalization; pediatric
• ISSN: 1058-4838; 1537-6591
• DOI: 10.1093/cid/ciz125

Abstract Background Influenza vaccine effectiveness (VE) varies by season, circulating influenza strain, age, and geographic location. There have been few studies of influenza VE among hospitalized children, particularly in Europe and the Middle East. Methods We estimated VE against influenza hospitalization among children aged 6 months to 8 years at Clalit Health Services hospitals in Israel in the 2015–2016, 2016–2017, and 2017–2018 influenza seasons, using the test-negative design. Estimates were computed for full and partial vaccination. Results We included 326 influenza-positive case patients and 2821 influenza-negative controls (140 case patients and 971 controls from 2015–2016, 36 case patients and 1069 controls from 2016–2017, and 150 case patients and 781 controls from 2017–2018). Over all seasons, VE was 53.9% for full vaccination (95% confidence interval [CI], 38.6%–68.3%), and 25.6% for partial vaccination (−3% to 47%). In 2015–2016, most viruses were influenza A(H1N1) and vaccine lineage–mismatched influenza B/Victoria; the VE for fully vaccinated children was statistically significant for influenza A (80.7%; 95% CI, 40.3%–96.1%) but not B (23.0%; −38.5% to 59.4%). During 2016–2017, influenza A(H3N2) predominated, and VE was (70.8%; 95% CI, 17.4%–92.4%). In 2017–2018, influenza A(H3N2), H1N1 and lineage-mismatched influenza B/Yamagata cocirculated; VE was statistically significant for influenza B (63.0%; 95% CI, 24.2%–83.7%) but not influenza A (46.3%; −7.2% to 75.3%). Conclusions Influenza vaccine was effective in preventing hospitalizations among fully vaccinated Israeli children over 3 influenza seasons, but not among partially vaccinated children. There was cross-lineage protection in a season where the vaccine contained B/Victoria and the circulating strain was B/Yamagata, but not in a season with the opposite vaccine-circulating strain distribution. Influenza vaccine was effective against influenza-associated hospitalization for fully vaccinated Israeli children, but not for partially vaccinated children. Vaccine-mediated cross-lineage protection against influenza B was seen for a trivalent vaccine containing B/Victoria but not for a B/Yamagata vaccine.